Stay updated with breaking news from Cardiovascular Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.
Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics Agreement grants Freeline rights to develop and commercialise AAV gene therapies using
Investegate announcements from Forcefield Therapeutics, Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics
Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients
23.03.2023 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today released its ...